{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:14:52Z","timestamp":1773288892404,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Tandem Control-IQ is an advanced hybrid closed loop (AHCL) system with a Sleep Activity Mode to intensify glycemic control overnight. The aim of the study is to evaluate the effectiveness of using Sleep Mode or not among Tandem Control-IQ users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Research design and methods<\/jats:title><jats:p>We performed a retrospective Tandem Control-IQ data download for patients followed at IRCCS G. Gaslini Pediatric Diabetes Centre. We divided the patients into group 1 (Sleep Mode users) and group 2 (non-users) and compared their overall glycemic data, particularly during nighttime.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Group 1 (<jats:italic>n<\/jats:italic> = 49) does not show better nocturnal glycemic control as expected when compared with group 2 (<jats:italic>n<\/jats:italic> = 34). Group 2 shows a nighttime TIR% of 69.50 versus 66.25 (<jats:italic>p<\/jats:italic> = 0.20). Only the patients who do not use Sleep Mode and with sensor and automatic mode use \u226590% reached TIR &amp;gt;70% during nighttime, as well as lower nocturnal TAR% (18.80 versus 21.78, <jats:italic>p<\/jats:italic> = 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first study that evaluates the real-life effectiveness of the use of Sleep Mode in young patients with T1D. Control-IQ Sleep Activity Mode may not be as effective in Italian patients as in American patients due to the different habits.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.996453","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:00:50Z","timestamp":1670821250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["To sleep or not to sleep: An Italian Control-IQ-uestion"],"prefix":"10.3389","volume":"13","author":[{"given":"Marta","family":"Bassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Francesca","family":"Strati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Andreottola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Calevo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"d\u2019Annunzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Minuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187","article-title":"Diabetes control and complications Trial\/Epidemiology of diabetes interventions and complications (DCCT\/EDIC) study research group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":". N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0031","article-title":"Time in range in children with type 1 diabetes using treatment strategies based on nonautomated insulin delivery systems in the real world","volume":"22","author":"Cherubini","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"B4","volume-title":"Device for Type 1 Diabetes","year":"2020"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11708","article-title":"Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes","volume":"316","author":"Bergenstal","year":"2016","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40124-021-00248-7","article-title":"Newest diabetes-related technologies for pediatric type 1 diabetes and its impact on routine care: a narrative synthesis of the literature","volume":"20","author":"Dos Santos","year":"2021","journal-title":"Curr Pediatr Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05391-w","article-title":"New closed-loop insulin systems","volume":"64","author":"Boughton","year":"2021","journal-title":"Diabetologia."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14273","article-title":"Hybrid closed-loop therapy: Where are we in 2021","volume":"23","author":"Leelarathna","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1249","article-title":"First look at control-IQ: A new-generation automated insulin delivery system","volume":"41","author":"Brown","year":"2018","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-Range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0011","article-title":"Successful At-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial","volume":"21","author":"Forlenza","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907863","article-title":"iDCL trial research group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004736","article-title":"iDCL trial research group. A randomized trial of closed-loop control in children with type 1 diabetes","volume":"383","author":"Breton","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1729","article-title":"iDCL trial research group. Extended use of the control-IQ closed-loop control system in children with type 1 diabetes","volume":"44","author":"Kanapka","year":"2021","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0572","article-title":"iDCL trial research group. closed-loop insulin therapy improves glycemic control in adolescents and young adults: Outcomes from the international diabetes closed-loop trial","volume":"23","author":"Isganaitis","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14491","article-title":"Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real-life study","volume":"23","author":"Cherubini","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.802419","article-title":"A comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes","volume":"12","author":"Bassi","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0097","article-title":"One year real-world use of the control-IQ advanced hybrid closed-loop technology","volume":"23","author":"Breton","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0165","article-title":"Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes","volume":"23","author":"Messer","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0532","article-title":"iDCL trial research group. health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control","volume":"23","author":"Cobry","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0388","article-title":"Real-world patient-reported outcomes and glycemic results with initiation of control-IQ technology","volume":"23","author":"Pinsker","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1778","article-title":"Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed loop system","volume":"45","author":"Cobry","year":"2022","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00592-022-01878-z","article-title":"vEC study group. significant and persistent improvements in time in range and positive emotions in children and adolescents with type 1 diabetes using a closed-loop control system after attending a virtual educational camp","volume":"21","author":"Rabbone","year":"2022","journal-title":"Acta Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.996453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T05:00:53Z","timestamp":1670821253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.996453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,12]]},"references-count":24,"alternative-id":["10.3389\/fendo.2022.996453"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.996453","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,12]]},"article-number":"996453"}}